Weekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer

Giovanna Masci, Chiara Gandini, Monica Zuradelli, Agnese Losurdo, Rosalba Torrisi, Selene Rota, Giuseppe Gullo, Laura Velutti, Laura Giordano, Armando Santoro

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Due to its low cardiac toxicity, nonpegylated liposomal doxorubicin (NPLD) may represent an attractive therapeutic option as salvage therapy for patients with metastatic breast cancer who have already received anthracycline-based chemotherapy. Patients and Methods: We retrospectively reviewed 47 consecutive patients with metastatic breast cancer treated with NPLD at our Institution between 2008 and 2012. Patients received weekly NPLD at a dose of 20 mg/m 2 i.v. until disease progression or unacceptable toxicity. Results: Nine patients (19.1%) achieved a partial response and 11 (23.4%) had stable disease, with a disease control rate of 42.6%; 27 patients (57.4%) had progressive disease. The median progression-free survival and overall survival were 2.7 and 11.5 months, respectively. Grade 3 and 4 adverse events did not occur. No cardiac events were observed. Conclusion: Weekly NPLD represents a safe and effective therapy and may be considered a new therapeutic option for heavily pre-treated patients with metastatic breast cancer.

Original languageEnglish
Pages (from-to)4603-4610
Number of pages8
JournalAnticancer Research
Volume33
Issue number10
Publication statusPublished - Oct 2013

Keywords

  • Anthracycline
  • Breast cancer
  • Metastatic breast cancer
  • Non-pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Weekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer'. Together they form a unique fingerprint.

Cite this